Cota

History

2020: The investment attraction from Varian

In the middle of November, 2020 Varian invested $10 million and signed the agreement on cooperation with the American developer of services for the analysis of oncological data of Cota. Under the terms of the agreement, Varian will offer the clients access to services of Cota who analyze data of electronic medical records and isolate the most important information.

Besides, Cota will work with Varian over development of new instruments of support of adoption of medical solutions within an initiative of Intelligent Cancer Care. The program is directed to improvement and further personalisation of treatment and care of oncological patients using advanced technologies, such as data analysis, machine learning and artificial intelligence.

Varian invested in the developer of services for the analysis of oncological data of Cota

Varian not for the first time supports Cota in the financial plan, and for 2020 total investment was $20 million, including in the form of a convertible loan. These financial injections give to Varian the chance to purchase Cota in the future.

The analytical Cota platform allows to take important information from medical records and to create data sets which are extremely necessary for efficiency evaluation of new drugs. For example, one of analytical tools uses possibilities of CNA - measurement of number of copies - for identification of patients according to phenotypical characteristics of tumors. It allows to create cohorts of patients who can appoint the identical, personalized on a phenotype treatment. Besides, when comparing different types of treatment in one cohort it will be possible to estimate their efficiency.

Thanks to cooperation with regulators, Cota can also create the data sets necessary for assessment of a check group of clinical trial. Such cohorts can replace group of placebo, and the patients participating in clinical trial will be able to receive experimental medicine at once.^[1]

Notes